The monoclonal antibodies belimumab and anifrolumab are both approved for the treatment of systemic lupus erythematosus (SLE). Their response is considered to be highly effective. The point at which they should be used in therapy was discussed on the basis of two case studies at the congress of the German Society for Internal Medicine (DGIM).
This content is machine-translated. Please contact us if you need professional translation services.
Autoren
- Jens Dehn
Publikation
- InFo RHEUMATOLOGIE
Related Topics
You May Also Like
- Cardiac arrhythmias
Atrial fibrillation – what do current guidelines say?
- PANCREATIC CELLS
Exploration map
- DIABETES AND OBESITY
Influence of movement and muscle regulation
- New studies on COPD
From inhalers, allergies and physical activity
- Rare diseases
The Alagille syndrome
- The future is near or here?
Ablation for atrial fibrillation
- Interventional valve therapy
Gender differences
- Anemia